Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 26.80M P/E - EPS this Y 32.80% Ern Qtrly Grth -
Income -34.03M Forward P/E -1.01 EPS next Y 28.50% 50D Avg Chg -8.00%
Sales 2.05M PEG -0.06 EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 0.51 EPS next 5Y 15.20% 52W High Chg -66.00%
Recommedations 1.80 Quick Ratio 5.16 Shares Outstanding 8.12M 52W Low Chg 11.00%
Insider Own 34.83% ROA -40.53% Shares Float 5.31M Beta 0.35
Inst Own 29.30% ROE -78.34% Shares Shorted/Prior 286.92K/293.57K Price 3.28
Gross Margin 100.00% Profit Margin - Avg. Volume 24,695 Target Price 22.50
Oper. Margin -1,211.14% Earnings Date May 1 Volume 15,511 Change -2.67%
About Lumos Pharma, Inc.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Lumos Pharma, Inc. News
04/18/24 Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
03/20/24 Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
03/10/24 Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
03/08/24 Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
03/07/24 Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
09:00 AM Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
02/05/24 Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
02/05/24 Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?
01/04/24 Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
11/21/23 Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
11/20/23 Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
11/07/23 Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
11/07/23 Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
08:00 AM Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
09/14/23 Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
09/07/23 Lumos Pharma Announces Participation in Investor Conferences in September
08/22/23 Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
08/09/23 Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
08:00 AM Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
07/12/23 Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
LUMO Chatroom

User Image Stock_Titan Posted - 1 week ago

$LUMO Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings https://www.stocktitan.net/news/LUMO/lumos-pharma-announces-abstracts-accepted-for-presentation-at-xj8hzk5nmdak.html

User Image NetworkNewsWire Posted - 1 month ago

BioMedNewsBreaks – $LUMO Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate https://ibn.fm/XRQbe

User Image Thestocktraderhubzee Posted - 1 month ago

WATCHLIST MAR 21 2024. $MAG Stifel Maintains Buy on MAG Silver, Lowers Price Target to $19 $AVGO Barclays Reinstates Overweight on Broadcom, Announces $1405 Price Target $LUMO HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target $NVDA Argus Research Maintains Buy on NVIDIA, Raises Price Target to $950 $ICCM Alliance Global Partners Maintains Buy on Icecure Medical, Raises Price Target to $2.9

User Image Thestocktraderhubzee Posted - 1 month ago

$LUMO HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target

User Image Stock_Titan Posted - 1 month ago

$LUMO Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 https://www.stocktitan.net/news/LUMO/lumos-pharma-announces-that-the-uspto-has-granted-patent-protection-g96rs81whrla.html

User Image My_Lai_1968 Posted - 1 month ago

$LUMO Looking to acquire shares at $1.12-$1.15 soon. Calamitous fall coming.

User Image Stocks4thought Posted - 1 month ago

$LUMO Will the AE's squash this one?

User Image Stu512 Posted - 1 month ago

$LUMO Careful ..here YEE speaks with a forth tongue

User Image Stocks4thought Posted - 1 month ago

$LUMO Head hunters trying to employ this one- after long - long slumber.

User Image Stocksearcher2022 Posted - 1 month ago

$CERO check out $LUMO new price targets of $28 and $16

User Image Bashay Posted - 1 month ago

$CERO bulls look at $LUMO, load some

User Image Bashay Posted - 1 month ago

$LUMO is it good ?

User Image Mugiwara38 Posted - 1 month ago

@CantNameThatTune $LUMO was $30 4 years ago in 2020. Just a quick spike probably due to a pump based on nothing that’s why it dropped rapidly after. Clearly Lumo is gonna stop to penny stock as $KZIA amd $KTRA did

User Image Stock_Titan Posted - 1 month ago

$LUMO Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update https://www.stocktitan.net/news/LUMO/lumos-pharma-reports-full-year-2023-financial-results-and-provides-iwkpvo98p8xv.html

User Image Manipulation13F Posted - 1 month ago

$LUMO 👀

User Image CantNameThatTune Posted - 02/29/24

$LUMO You people on $ENVB and $RVSN need to learn how to play the market. You load dips and sell runs. SWIN $.730 dip this AM now $13's.

User Image Stock_Titan Posted - 2 months ago

$LUMO Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 https://www.stocktitan.net/news/LUMO/lumos-pharma-to-report-full-year-2023-financial-results-and-host-iyq4npyhovli.html

User Image fda_tracker Posted - 2 months ago

$LUMO Phase 2 trial w/est Feb completion date NCT04614337: https://www.clinicaltrials.gov/study/NCT04614337 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image CantNameThatTune Posted - 2 months ago

You people on $BTAI $FDMT $CRBP $VYGR likely have never heard of $LUMO. A few weeks ago they announced trial data clearly illustrating they have found a cure for pediatric growth hormone deficiency. The stock rose $3 to new 52 week highs at $9.13 after hours. The idiots couldn't stand it and sold into it right back down to $3. Since that day, JP Morgan has been buying and just announced a 5.1% stake in the company. Conveniently right before LUMO releases data at Oppenheimer's big Life Sciences Conference next Wednesday. Oh yeah. Wells Fargo announced a 5.3% stake in LUMO two days ago. For the exact same reason. Because LUMO has targets of $26-$28. That is until both JP and WF announce their $30-$40 targets. LUMO is $3.

User Image Stock_Titan Posted - 2 months ago

$LUMO Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference https://www.stocktitan.net/news/LUMO/lumos-pharma-to-participate-in-oppenheimer-s-34th-annual-healthcare-3omjuuii05ef.html

User Image cdlawton07 Posted - 01/29/24

$LUMO trimmed my stake down a bit to free my money up to put some into MPW. Still waiting for that FDA meeting/partnership announcement. Sitting on 2,000 shares.

User Image wavehog Posted - 3 months ago

$LUMO see u at 1

User Image wavehog Posted - 3 months ago

$LUMO still not seeing 3🤡

User Image wavehog Posted - 3 months ago

$LUMO told u

User Image wavehog Posted - 3 months ago

$LUMO might not get above 3 again-this one is toast

User Image PamelaByrge Posted - 3 months ago

$LUMO Started trading over 4 months ago and I lost $3K. Now I've made over $177K+ profits after joining their chat room and using their alerts.. Highly recommended! It's free joining.,💨💁‍♂️ stocks-great-winning-trades.profitablestocks.vip/

User Image fda_tracker Posted - 3 months ago

$LUMO Phase 2 trial w/est Jan completion date NCT05250063: https://www.clinicaltrials.gov/study/NCT05250063 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image Telefon Posted - 3 months ago

$ELTP Elite Pharmaceuticals Inc is a company that specializes in the development and manufacturing of generic products. The company focuses on controlled-release drug delivery systems and abuse-deterrent technologies and owns multiple generic products which have been licensed to Prasco LLC and TAGI Pharma. ELTP's operating profits are up 73% over the past year, and the share price has tripled since August. The company is in the process of expanding manufacturing and storage capacity to meet the unprecedented demand for Adderall as a result of a nationwide shortage. They announced the first shipment of generic Adderall XR to Prasco in December. Elite could reach at least $200 million in annual revenues in 1-2 years based on drugs already at or being prepared for submission to FDA. $NSTGQ $MBRX $LUMO $CRBP

User Image tickeron Posted - 3 months ago

This is amazing! What do you think? $LUMO MACD Histogram turned negative on January 12, 2024. View odds of downtrend. https://srnk.us/go/4968656

User Image tickeron Posted - 3 months ago

How will this affect the market? $LUMO Stochastic Oscillator left the oversold zone. View odds of downtrend. https://srnk.us/go/4967100

Analyst Ratings
HC Wainwright & Co. Buy Mar 20, 24
Oppenheimer Outperform Mar 8, 24
HC Wainwright & Co. Buy Mar 8, 24
Oppenheimer Outperform Dec 11, 23
HC Wainwright & Co. Buy Dec 7, 23
HC Wainwright & Co. Buy Sep 6, 23
Cantor Fitzgerald Overweight Aug 22, 23
Cantor Fitzgerald Overweight Aug 15, 23
Oppenheimer Outperform Aug 10, 23